Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price reached a new 52-week low on Saturday . The stock traded as low as $14.79 and last traded at $15.87, with a volume of 9825974 shares traded. The stock had previously closed at $23.05.

Analysts Set New Price Targets

Several research firms have recently weighed in on DYN. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday. Royal Bank of Canada started coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research report on Friday. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. Finally, Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Trading Down 31.1 %

The firm’s fifty day moving average price is $27.04 and its 200-day moving average price is $34.02. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -4.46 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the sale, the director now owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the sale, the director now owns 99,652 shares in the company, valued at $3,522,698.20. This represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,742 shares of company stock valued at $1,443,246. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DYN. AQR Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after purchasing an additional 352 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the period. KBC Group NV boosted its holdings in Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares during the period. Amalgamated Bank boosted its holdings in Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Dyne Therapeutics in the third quarter worth $34,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.